Moreover, vMO modified Bcl-xSSOs was found to correct aberrant splicing of Bcl-x in CML cells and improve therapeutic sensitivity to imatinib mesylate significantly [5, 148]. The gene discussed is BCL2L1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.